Mithra logo.jpg
Mithra reports full year 2023 financial results
08 mars 2024 01h00 HE | Mithra Pharmaceuticals
Mithra reports full year 2023 financial results Revenues were EUR 40.2 million, down from the 2022 result of EUR 67.0 million which was positively impacted by exceptional upfront cash payments from...
Mithra logo.jpg
Mithra announces changes to its executive management
05 mars 2024 01h01 HE | Mithra Pharmaceuticals
Mithra announces changes to its executive management Liege, Belgium, 05 March 2024 – 07:00 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces the...
Mithra logo.jpg
Mithra initiates monetization process, receives bridge loan from existing lenders
05 mars 2024 01h00 HE | Mithra Pharmaceuticals
   Mithra initiates monetization process, receives bridge loan from existing lenders Mithra appoints advisors and initiates a process to monetize its assets or execute a sale of its businessMithra...
Mithra logo.jpg
DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase
29 févr. 2024 05h42 HE | Mithra Pharmaceuticals
          DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase Mithra on-track for completion of Phase 3 study for DONESTA® to treat...
Mithra logo.jpg
Mithra sells shares in Mayne Pharma
15 févr. 2024 12h23 HE | Mithra Pharmaceuticals
          Mithra sells shares in Mayne Pharma Mithra sold all 4,221,815 shares it held in Mayne Pharma for EUR ~12.8 millionAs the Mayne Pharma shares were pledged to the secured lenders of Mithra,...
Mithra logo.jpg
Mithra updates on cash position
06 févr. 2024 01h00 HE | Mithra Pharmaceuticals
          Mithra updates on cash position Mithra's current cash of EUR 6.5 million is expected to cover its current cash runway through early MarchMithra is actively engaging with...
Mithra logo.jpg
Mithra updates on cash position
06 févr. 2024 01h00 HE | Mithra Pharmaceuticals
          Mithra updates on cash position Mithra's current cash of EUR 6.5 million is expected to cover its current cash runway through early MarchMithra is actively engaging with...
Mithra logo.jpg
Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel
21 déc. 2023 11h45 HE | Mithra Pharmaceuticals
          Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel Rafa Laboratories to receive the exclusive commercial rights for DONESTA® in Israel on the...
Mithra logo.jpg
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients
20 déc. 2023 11h45 HE | Mithra Pharmaceuticals
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients Important milestone for Mithra’s commitment to bring benefits of ESTELLE® to more womenPotential EMA approval in pediatric...
Mithra logo.jpg
Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial
18 déc. 2023 01h00 HE | Mithra Pharmaceuticals
Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial The DSMB recommends continuing the phase 3 trial in Europe following regular safety assessmentThe menopause phase 3 program...